Future Oncology
Volume 16, 2020 - Issue 15
Open access
5,738
Views
7
CrossRef citations to date
0
Altmetric
Research Article
Real-World Treatment Duration in ALK-Positive Non-Small-Cell Lung Cancer Patients Receiving Brigatinib Through the Early Access Program
Huamao M Lin1 Millennium Pharmaceuticals, Inc.,Cambridge,MA02139,USACorrespondence[email protected]
View further author information
, View further author information
Xiaoyun Pan2 EMD Serono, Inc.,Billerica,MA01821,USAView further author information
, Peijie Hou3 Regeneron Pharmaceuticals, Inc.,Tarrytown,NY10591,USAView further author information
, Susan Allen1 Millennium Pharmaceuticals, Inc.,Cambridge,MA02139,USAView further author information
, Pia Baumann1 Millennium Pharmaceuticals, Inc.,Cambridge,MA02139,USAView further author information
& Maximilian J Hochmair4 Karl Landsteiner Institute of Lung Research & Pulmonary Oncology,Department of Respiratory & Critical Care Medicine,Krankenhaus Nord,Vienna,AustriaView further author information
Pages 1031-1041
|
Received 23 Dec 2019, Accepted 20 Mar 2020, Published online: 27 Apr 2020
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.